Get started
Author

Lauren Brusco

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
2015 · Funda Meric-Bernstam, Lauren Brusco, et al. · Journal of Clinical Oncology · 425
PDF
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
2015 · Funda Meric-Bernstam, Amber Johnson, et al. · JNCI Journal of the National Cancer Institute · 199
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
2016 · F. Meric-Bernstam, L. Brusco, et al. · Annals of Oncology · 196
Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling
2010 · Ines Barone, Lauren Brusco, et al. · Clinical Cancer Research · 159
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer
2018 · Funda Meric-Bernstam, Xiaofeng Zheng, et al. · JCO Precision Oncology · 76
Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer
2015 · Andrew Ciupek, Yassine Rechoum, et al. · Breast Cancer Research and Treatment · 54
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.
2014 · Ann M Bailey, Yong Mao, et al. · PubMed · 53
Loss of Rho GDIα and Resistance to Tamoxifen via Effects on Estrogen Receptor α
2011 · Ines Barone, Lauren Brusco, et al. · JNCI Journal of the National Cancer Institute · 52
PDF
Clinical next generation sequencing to identify actionable aberrations in a phase I program
2015 · Genevieve M. Boland, Sarina A. Piha-Paul, et al. · Oncotarget · 46
PDF
Clinical Use of Precision Oncology Decision Support
2017 · Amber Johnson, Yekaterina B. Khotskaya, et al. · JCO Precision Oncology · 42
“Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource
2017 · Katherine C. Kurnit, Ann M. Bailey, et al. · Cancer Research · 41
Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer
2013 · Kyle R. Covington, Lauren Brusco, et al. · Breast Cancer Research and Treatment · 41
Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations
2019 · Ecaterina Ileana Dumbrava, Lauren Brusco, et al. · JCO Precision Oncology · 17
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
2017 · Natalia Paez Arango, Lauren Brusco, et al. · Oncotarget · 13
PDF
Physician interpretation of genomic test results and treatment selection
2017 · Lauren L. Brusco, Chetna Wathoo, et al. · Cancer · 12
PDF
Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.
2015 · Funda Meric-Bernstam, Lauren Brusco, et al. · Journal of Clinical Oncology · 6
Active Disclosure of Secondary Germline Findings to Deceased Research Participants’ Personal Representatives: Process and Outcomes
2017 · Molly Daniels, Chetna Wathoo, et al. · JCO Precision Oncology · 5
PDF
Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.
2017 · Ecaterina Elena Ileana Dumbrava, Lauren Brusco, et al. · Journal of Clinical Oncology · 1
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.
2017 · Ecaterina Elena Ileana Dumbrava, Lauren Brusco, et al. · Journal of Clinical Oncology · 1
1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials
2014 · F. Meric-Bernstam, L. Brusco, et al. · European Journal of Cancer · 1
Clinical next-generation sequencing to identify actionable alterations in a phase I program.
2014 · Genevieve Marie Boland, Sarina Anne Piha-Paul, et al. · Journal of Clinical Oncology · 1
Supplementary Video S1 from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource
2024 · Katherine C. Kurnit, Ann M. Bailey, et al.
Supplementary Video S1 from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource
2024 · Katherine C. Kurnit, Ann M. Bailey, et al.
Data from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource
2024 · Katherine C. Kurnit, Ann M. Bailey, et al.
Supplementary Video S1 from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource
2024 · Katherine C. Kurnit, Ann M. Bailey, et al.
Works count: 37
Citation count: 1,441
H-index: 13
I10-index: 15
Year
Topic
Type